ContraVir Pharmaceuticals, Inc,.a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from...
SinuSys Corp has announced receipt of the CE Mark for Vent-Os Sinus Dilation System, a low-pressure, self-expanding dilation device to...
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus surgery.
The European Commission approved a new indication for Dupixent (dupilumab), from Sanofi, in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent...
Intersect ENT announced the first presentation of results from RESOLVE II, a randomized, double-blinded, controlled Phase III clinical trial, which...
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score ≥ 10 at baseline.
The aim of our study was to compare the time to conversion and the conversion rate within 90 min in patients with recent-onset atrial fibrillation treated with vernakalant or ibutilide.
Detailed results were presented from two Phase III trials using Dupixent (dupilumab), from Sanofi, in patients with recurring severe chronic...
Objective: We report the effect of dupilumab vs placebo on outcome measures of the upper and lower airways and health-related quality of life (HRQoL) in the pooled population of patients with CRSwNP and comorbid asthma from the phase 3 SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) studies.